Recent clinical introduction of anti-vascular endothelial growth factor agents may change the clinical course of macular diseases, including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), central serous chorioretinopathy (CSC), myopic choroidal neovascularization (CNV), retinal vein occlusion (RVO), diabetic macular edema (DME), and so forth. Patients with such macular diseases are registered and and are followed up for 5 years with appropriate treatment for each patient. By the analysis of the correlation between initial examinations and final visual acuity, factors associated with good visual prognosis will be elucidated.
Study Type
OBSERVATIONAL
Enrollment
1,000
Kyoto University Graduate School of Medicine
Kyoto, Kyoto, Japan
RECRUITINGInitial factors associated with visual prognosis in each macular disease
Time frame: Five years after the registration
The difference in the visual prognosis depending on the treatments in each macular diseases
Time frame: Five years after the registration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.